UTHR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
United Therapeutics Corp (UTHR) is not a strong buy for a beginner, long-term investor at this moment. While the company has demonstrated solid financial growth and analysts maintain a positive outlook with an increased price target, the lack of recent positive news, neutral insider and hedge fund trading trends, and absence of strong trading signals suggest that the current price does not present an optimal entry point. The technical indicators show a bullish trend, but the stock's short-term price movement probabilities are not compelling enough to justify immediate action.
The technical indicators are bullish, with MACD positively expanding, RSI in the neutral zone, and moving averages aligned in a bullish pattern (SMA_5 > SMA_20 > SMA_200). The stock is trading above key support levels, with a pivot at 477.302 and resistance levels at 486.875 and 492.79.
Analysts have raised the price target to $645, indicating confidence in the stock's long-term potential.
Strong financial performance in Q3 2025, with revenue, net income, and EPS showing healthy YoY growth.
No recent positive news or event-driven catalysts.
Neutral insider and hedge fund trading trends.
Gross margin dropped slightly YoY, which may indicate some pressure on profitability.
In Q3 2025, United Therapeutics reported a 6.76% YoY increase in revenue, a 9.58% YoY increase in net income, and a 12.05% YoY increase in EPS. However, gross margin declined by 1.71% YoY to 87.38%.
UBS raised the price target to $645 from $600 and maintained a Buy rating. Analysts are cautiously optimistic about the biotech sector, with potential M&A activity being a key driver for sustained outperformance.
